13D Filing: Longwood Fund II, L.P. and Kalvista Pharmaceuticals Inc. (KALV)

Names of
Reporting Persons.

Christoph Westphal, M.D.,
Ph.D.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

SEC Use Only

Source of Funds (See Instructions)

AF

Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e)  ☐

Citizenship or Place of
Organization

USA

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

934,484 shares, all of which 934,484 shares are directly owned by LFII, except that LFII
GP, as the general partner of LFII, may be deemed to have sole power to vote LFIIs shares (collectively, the Fund II Shares), and Aldrich, a manager and member of LFII GP and member of the Board of Directors of the Issuer, may be
deemed to have shared power to vote the Fund II Shares.

Shared Voting Power

See response to row 7.

Sole Dispositive Power

934,484 shares, all of which 934,484 shares are directly owned by LFII, except that LFII
GP, as general partner of LFII, maybe deemed to have sole power to dispose of the Fund II Shares, and Aldrich, as a manager and member of LFII GP and member of the Board of Directors of the Issuer, may be deemed to have shared power to dispose of
the Fund II Shares.

Shared Dispositive Power

See response to row 9.

Aggregate Amount Beneficially Owned by Each Reporting Person

934,484

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)  ☐

Percent of Class Represented by Amount
in Row (11)

8.7%*

Type of Reporting Person (See
Instructions)

IN